Lincoln Pharmaceuticals Limited, a leading healthcare company based in Gujarat, India, has announced strong financial results for the first quarter, along with significant corporate governance decisions.

Financial Performance

The company reported a standalone net profit of Rs. 27.70 crore for Q1, marking a 16.93% year-on-year growth compared to Rs. 23.69 crore in the same quarter of the previous year. Total income for the quarter rose by 7.39% to Rs. 169.34 crore, up from Rs. 157.69 crore in the corresponding period last year.

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) showed a substantial increase of 17.92% year-on-year, reaching Rs. 39.08 crore compared to Rs. 33.14 crore in the same quarter of the previous fiscal year. The company's earnings per share (EPS) for the quarter stood at Rs. 13.82.

Corporate Governance

In a recent board meeting, Lincoln Pharmaceuticals made several key decisions regarding its leadership:

1. Mahendra G. Patel was re-appointed as Managing Director for a five-year term from October 1, 2025, to September 30, 2030.
2. Hashmukh I. Patel was re-appointed as Whole Time Director for the same period.
3. Ashish R. Patel and Munjal M. Patel were both re-appointed as Whole Time Directors for five-year terms from November 14, 2025, to November 13, 2030.

These re-appointments are subject to shareholder approval at the upcoming Annual General Meeting.

Business Expansion and Future Outlook

Lincoln Pharmaceuticals has set ambitious targets for growth:

• The company aims to achieve a revenue of Rs. 1,000 crore within the next three years.
• It is targeting an annual growth rate of 15-18%, driven by strong performance in cardiac, diabetic, dermatology, and ENT segments.
• The company plans to expand its global footprint from the current 60+ countries to 90 countries in the next 2-3 years.

Mahendra Patel, Managing Director, highlighted that the company has started a Bulk Drug Manufacturing Plant, with product approvals received for 10 products and others in process. The company plans to invest Rs. 4 crore in this plant from internal accruals.

Investor Confidence

Foreign Institutional Investors (FIIs) have shown increased confidence in Lincoln Pharmaceuticals, raising their stake from 3.95% to 5.13% over the past year.

Conclusion

Lincoln Pharmaceuticals' strong quarterly results, coupled with its strategic re-appointments and expansion plans, indicate a positive outlook for the company. As it continues to focus on innovation and global expansion, the company appears well-positioned for sustained growth in the pharmaceutical sector.

Lincoln Pharmaceuticals , a leading Indian healthcare company, has reported robust financial results for the first quarter, showcasing significant growth and outlining ambitious future plans.

Q1 Financial Highlights

Lincoln Pharma's Q1 results demonstrate strong performance across key financial metrics:

*All figures in ₹ crore

The company reported a standalone net profit of ₹27.70 crore for Q1, marking a 17% increase from ₹23.69 crore in the same period last year. Total income rose by 7.3% year-over-year to ₹169.34 crore. Notably, EBITDA showed impressive growth, reaching ₹39.08 crore, up 17.92% from ₹33.14 crore in Q1 of the previous year.

Strategic Growth and Expansion

Lincoln Pharmaceuticals has set ambitious targets for the coming years:

1. Revenue Goal: The company aims to achieve ₹1,000 crore in revenue within the next three years.
2. Annual Growth Rate: Lincoln Pharma is targeting a 15-18% annual growth rate.
3. Key Growth Segments: The company's growth strategy focuses on strong performance in cardiac, diabetic, dermatology, and ENT segments.
4. Business Expansion: The company plans to expand into high-value product lines and new markets.

Recent Developments

• Bulk Drug Manufacturing: During the quarter, the company launched its bulk drug manufacturing plant with a ₹4 crore investment from internal funds.
• Product Approvals: The company received approvals for 10 products.
• Stock Performance: Company shares surged 8.47% to close at ₹576.90 on BSE.

Company Profile

Lincoln Pharmaceuticals, established in 1979, has developed over 600 formulations across various therapeutic areas. The company's product portfolio includes treatments for anti-infective, respiratory, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, and anti-malarial conditions.

As Lincoln Pharmaceuticals continues to expand its product range and global presence, the company remains focused on providing affordable and innovative medicines for healthier lives, aligning with its vision of "Healthcare for All."